POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (10.22.2021, 5:45pm CEST, WHO):   U.S. 74,227    India 15,786    Brazil 15,609    United Kingdom 51,484    Russia 37,141    Turkey 28,465    France 5,498    Iran 11,788    Argentina 1,218    Columbia 1,224    Italy 3,791    Germany 19,572    Mexico 5,069    Poland 5,716    Philippines 4,806    Ukraine 23,785    Malaysia 6,210    Peru 1,034    Netherlands 5,223    Iraq 1,882    Thailand 9,810    Czechia 3,638    Canada 2,641    Chile 1,793    Romania 15,410    Serbia 7,327    Kazakhstan 1,893    Cuba 1,435    Vietnam 3,636    Hungary 2,548    Austria 3,818    Greece 3,376    Georgia 4,155    Belarus 2,097    Bulgaria 4,816    Azerbaijan 2,005    Slovakia 3,470    Croatia 3,258    Ireland 2,026    Venezuela 1,254    Lithuania 3,016    Denmark 1,247    South Korea 1,440    Moldova 1,787    Slovenia 1,845    Armenia 2,146    Latvia 3,133    Estonia 1,323    China 51    Singapore 3,439    New Zealand 134    Australia 2,643   

BioVaxys prepares for groundbreaking study on SARS-CoV-2 proteins

Christian Fernsby |
BioVaxys Technology announced that it has initiated what could be a scientifically groundbreaking study on the reduced ACE2 binding capabilities of the hapten-modified spike protein that is the foundation of BVX-0320, the Company's SARS-CoV-2 vaccine.

Article continues below

Many SARS-CoV-2-infected patients develop pneumonia that may lead to acute respiratory distress, with some patients developing cardiac symptoms and cardiovascular injury.

In their peer-reviewed research paper, "SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19," published in the Journal of Hematological Oncology, S. Zhang conclude that the Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein binds to the ACE2 receptor and that this binding of SARS-CoV-2 to ACE2 prevents the enzyme from converting angiotensin II, potentiating pulmonary and cardiovascular issues.

Currently available vaccines, whether comprised of recombinant full-length or partial spike protein can result in rare, but life-threatening side effects, such as abnormal blood clotting or myocarditis.

These toxicities may be caused by unwanted binding of the vaccine spike protein to ACE2 receptors in the heart or platelet factor 4.

The Biovaxys vaccine for COVID-19, BVX-0320, comprises a portion of the spike protein that is modified by the hapten, dinitrophenyl (DNP). Biovaxys believes that the haptenized spike protein has much diminished ability to bind to ACE2, which would result in much diminished vaccine toxicity.

David Berd, MD, Chief Medical Officer of Biovaxys, explained that "Biovaxys will compare the binding of haptenized spike protein with the non-haptenized. The results could provide evidence that our vaccine has lowered potential for some of the observed serious vaccine side effects."

James Passin, BioVaxys CEO, stated, "Haptenization, as a method to inhibit the ACE2-binding ability of the spike protein, while increasing its immunogenicity, may prove to play a critical role in global COVID-19 vaccine development and deployment strategies, as public health authorities consider options for repeated seasonal vaccine boosters in the context of reported, albeit rare, adverse effects and apparent waning immunity."

BioVaxys is currently finalizing arrangements with a major U.S. academic research institution who will be collaborating with the Company on the study.

For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.

What to read next

Synthetic biology used to target cancer cells while sparing healthy tissue
How life arose from primordial muck
Autism linked to egg cells' difficulty creating large proteins